Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis

被引:11
|
作者
Quan, Hongzhi [1 ,2 ,3 ,4 ,5 ,6 ]
Liu, Sixuan [1 ,2 ,3 ,4 ,5 ,6 ]
Shan, Zhongyan [1 ,2 ,3 ,4 ,5 ,6 ]
Liu, Ziyi [1 ,2 ,3 ,4 ,5 ,6 ]
Chen, Tianjun [1 ,2 ,3 ,4 ,5 ,6 ]
Hu, Yanjia [1 ,2 ,3 ,4 ,5 ,6 ]
Yao, Zhigang [1 ,2 ,3 ,4 ,6 ,7 ]
Fang, Liangjuan [8 ,9 ]
机构
[1] Cent South Univ, Hunan Key Lab Oral Hlth Res, Changsha 410008, Hunan, Peoples R China
[2] Cent South Univ, Hunan 3D Printing Engn Res Ctr Oral Care, Changsha 410008, Hunan, Peoples R China
[3] Cent South Univ, Hunan Clin Res Ctr Oral Major Dis & Oral Hlth, Xiangya Stomatol Hosp, Changsha 410008, Hunan, Peoples R China
[4] Cent South Univ, Xiangya Sch Stomatol, Changsha 410008, Hunan, Peoples R China
[5] Cent South Univ, Dept Oral Maxillofacial Surg, Xiangya Stomatol Hosp, Changsha 410008, Hunan, Peoples R China
[6] Cent South Univ, Sch Stomatol, Changsha 410008, Hunan, Peoples R China
[7] Cent South Univ, Xiangya Stomatol Hosp, Dept Oral Pathol, Changsha 410008, Hunan, Peoples R China
[8] Cent South Univ, Xiangya Hosp, Dept Neurol, Changsha 410008, Hunan, Peoples R China
[9] Cent South Univ, Key Lab Hunan Prov Neurodegenerat Disorders, Changsha 410008, Hunan, Peoples R China
基金
中国博士后科学基金;
关键词
Oral squamous cell carcinoma; Oral submucous fibrosis; Programmed death ligand-1; Programmed death 1; Prognosis; PD-L1; EXPRESSION; CANCER; MICROENVIRONMENT; BLOCKADE; GRADE;
D O I
10.1016/j.archoralbio.2020.104916
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Objective: The aim of our study was to investigate the expression of programmed death ligand-1 (PD-L1)/programmed death-1 (PD-1) between oral squamous cell carcinoma (OSCC) patients with and without oral submucous fibrosis (OSF), and its correlation with clinic-pathologic features and its prognostic value. Methods: PD-L1 and PD-1 expression was evaluated by immunohistochemical staining, double immunofluorescent staining and real-time PCR, and the correlation of PD-L1/PD-1 expression with clinical outcome was assessed. Results: The level of PD-L1 expression was significantly higher in OSCC with OSF than in OSCC without OSF = 0.006). Moreover, PD-L1 expression was strongly correlated with lymph node metastasis (p = 0.016), and advanced tumor stage (p = 0.030). Increased PD-L1 expression was positively correlated with the incidence of OSCC with OSF = 0.006, p = 0.008, respectively). PD-L1 expression was an independent marker of unfavorable prognosis (p = 0.035, p = 0.048, respectively). High PD-L1 expression had a significantly worse outcome in OSCC patients with OSF (p = 0.014). Double immunofluorescent staining showed that OSCC with OSF were more strongly expressed both PD-L1 and PD-1 than OSCC without OSF. Moreover, the expression of PD-L1 were upregulated in OSCC tissues than normal control (p = 0.0422), and both PD-L1 and PD-1 was significantly higher in OSCC with OSF than OSCC without OSF tissues (p = 0.0043 and, p = 0.0012, respectively). Conclusions: The present study suggested that PD-L1 may be an unfavorable indicator for prognosis. PD-L1/PD-1 signaling might play an important role in the malignant transformation of OSF, and targeting PD-L1/PD-1 signaling may be a new therapeutic strategy for OSCC, especially in OSCC patients with OSF.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action
    Zhang, Ni
    Tu, Jingyao
    Wang, Xue
    Chu, Qian
    IMMUNOTHERAPY, 2019, 11 (05) : 429 - 441
  • [22] The clinicopathological features of programmed death ligand-1 expression in colorectal carcinoma
    Al-Jussani, Ghada N.
    Alsughayer, Anas
    Yousuf, Mustafa S.
    Mullahuwash, Yaseen
    Dabbagh, Tamara
    Sughayer, Maher A.
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2022, 37 (03) : 322 - 327
  • [23] Synergistic effect of programmed death-1 inhibitor and programmed death-1 ligand-1 inhibitor combined with chemotherapeutic drugs on DLBCL cell lines in vitro and in vivo
    Zhang, Rui
    Lyu, Cuicui
    Lu, Wenyi
    Pu, Yedi
    Jiang, Yanyu
    Deng, Qi
    AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (09): : 2800 - 2812
  • [24] Immune Checkpoint Gene Expression Profiling Identifies Programmed Cell Death Ligand-1 Centered Immunologic Subtypes of Oral and Squamous Cell Carcinoma With Favorable Survival
    Yu, Yang
    Tang, Huiwen
    Franceschi, Debora
    Mujagond, Prabhakar
    Acharya, Aneesha
    Deng, Yupei
    Lethaus, Bernd
    Savkovic, Vuk
    Zimmerer, Ruediger
    Ziebolz, Dirk
    Li, Simin
    Schmalz, Gerhard
    FRONTIERS IN MEDICINE, 2022, 8
  • [25] Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype
    Satgunaseelan, Laveniya
    Gupta, Ruta
    Madore, Jason
    Chia, Noel
    Lum, Trina
    Palme, Carsten E.
    Boyer, Michael
    Scolyer, Richard A.
    Clark, Jonathan R.
    PATHOLOGY, 2016, 48 (06) : 574 - 580
  • [26] Inflammation promotes oral squamous carcinoma immune evasion via induced programmed death ligand-1 surface expression
    Lu, Wanlu
    Lu, Libing
    Feng, Yun
    Chen, Jiao
    Li, Yan
    Kong, Xiangli
    Chen, Sixiu
    Li, Xiaoyu
    Chen, Qianming
    Zhang, Ping
    ONCOLOGY LETTERS, 2013, 5 (05) : 1519 - 1526
  • [27] Expression of programmed cell death ligand 1 and programmed cell death 1 in cutaneous warts
    Yu, Wesley Y.
    Berger, Timothy G.
    North, Jeffrey P.
    Laszik, Zoltan
    Cohen, Jarish N.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (05) : 1127 - 1133
  • [28] Prognostic effect of programmed cell death ligand 1/programmed cell death 1 expression in cancer stem cells of human oral squamous cell carcinoma
    Todoroki, Keita
    Abe, Yushi
    Matsuo, Katsuhisa
    Nomura, Hidetoshi
    Kawahara, Akihiko
    Nakamura, Yoshiaki
    Nakamura, Moriyoshi
    Seki, Naoko
    Kusukawa, Jingo
    ONCOLOGY LETTERS, 2024, 27 (02)
  • [29] Programmed Cell Death-1/ Ligand-1 PET Imaging A Novel Tool to Optimize Immunotherapy?
    Verhoeff, Sarah R.
    van den Heuvel, Michel M.
    van Herpen, Carla M. L.
    Piet, Berber
    Aarntzen, Erik H. J. G.
    Heskamp, Sandra
    PET CLINICS, 2020, 15 (01) : 35 - 43
  • [30] Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma
    Yokoyama, Shintaro
    Miyoshi, Hiroaki
    Nakashima, Kazutaka
    Shimono, Joji
    Hashiguchi, Toshihiro
    Mitsuoka, Masahiro
    Takamori, Shinzo
    Akagi, Yoshito
    Ohshima, Koichi
    CLINICAL CANCER RESEARCH, 2016, 22 (18) : 4727 - 4734